Immune thrombocytopenia is an autoimmune disorder characterised by accelerated platelet destruction and impaired production, resulting in variable thrombocytopenia and bleeding risk. First-line treatment with corticosteroids and intravenous immunoglobulin is established; thrombopoietin receptor agonists eltrombopag and romiplostim are standard second-line options. Novel treatments targeting the FcRn receptor and B-cell pathways are expanding the therapeutic landscape.
Monoclonal Antibodies May Complicate Transfusion Testing
Monoclonal antibodies, particularly IgG4 anti-CD47, may induce erythrophagocytosis and interfere with transfusion compatibility testing, posing a challenge for patient management.
ITP Management: Bridging Clinician and Patient Perspectives
Chronic immune thrombocytopenia (ITP) management: a clinical review aligning physician treatment strategies with patient quality-of-life priorities, long-term outcomes, and disease burden in chronic ITP.
Immune Drivers in Autoimmune Cytopenias Inform Patient Care
Understanding immune drivers in autoimmune cytopenias, discussed at EHA 2026, offers insights into targeted therapies and improved patient management.
Caplacizumab Improves iTTP Outcomes in Real-World Settings
Real-world data presented at EHA 2026 confirm caplacizumab's efficacy in immune-mediated thrombotic thrombocytopenic purpura (iTTP), reducing refractory disease and mortality.
Rare Conditions: EHA 2026 Highlights Diagnostic Challenges
EHA 2026 session 'The Sherlock Holmes Approach' addressed diagnostic delays in rare haematological conditions, emphasizing systematic clinical reasoning.